By Daniella Parra
Vivani Medical said it received regulatory approval in Australia for its GLP-1 (exenatide) implant, aimed at treating obese and overweight individuals.
The trial will evaluate the safety, tolerability and pharmacokinetic profile of the implant, which is designed to offer comparable efficacy to semaglutide, the active ingredient in Ozempic and Wegovy, but with only twice-yearly administration, it said.
“We remain confident that our emerging portfolio of miniature, ultra long-acting, GLP-1 implants has the potential to be highly differentiated from the injectable and oral products in the market and in development,” said Adam Mendelsohn, Ph.D., Vivani President and CEO. “Specifically, our implants are uniquely designed to address medication non-adherence, a critical challenge for many patients which we believe represents the largest opportunity to improve real world health outcomes for patients, and the steady delivery of medicine enabled by our NanoPortal technology may also improve treatment tolerability.”
Contact:
Editor@executives-edge.com
